GE Healthcare, a unit of General Electric Company (NYSE: GE), announced today that it is extending its previously announced tender offer for all of the outstanding capital stock of Clarient, Inc. (Nasdaq: CLRT) until 12:00 midnight, New York City time, on Thursday, December 16, 2010.
The tender offer has been extended to allow investors to consider revised disclosures in an amendment to Clarient's Solicitation/Recommendation Statement on Schedule 14D-9 made pursuant to a Memorandum of Understanding entered into on behalf of Clarient, General Electric and Crane Merger Sub, Inc., an indirect, wholly-owned subsidiary of General Electric, outlining the terms of the parties' agreement in principle to settle the actions pending in the Delaware Court of Chancery captioned In re Clarient, Inc. Shareholder Litigation, C.A. No. 5932-CC and the Superior Court of California, County of Orange captioned Herbert Silverberg v. Clarient, Inc., Master File No. 30-2010-00419685-CU-MC-CXC. The terms of the proposed settlement are subject to approval by the Delaware Court of Chancery.
As announced previously, on November 5, 2010, GE Healthcare, through Crane Merger Sub, commenced a tender offer for all of the outstanding shares of common and preferred stock of Clarient at $5.00 in cash per common share and $20.00 in cash per preferred share, in each case without interest and less any required withholding taxes. The tender offer was previously scheduled to expire at 12:00 midnight, New York City time, on Monday, December 6, 2010. All other terms and conditions of the tender offer remain unchanged.
As of 5:00 p.m. on December 2, 2010, approximately 42,348,047 common shares of Clarient and 5,263,158 preferred shares of Clarient (which were automatically converted into common shares after the date of tender in accordance with their terms) had been tendered and not withdrawn pursuant to the tender offer, representing approximately 47.7% of the outstanding common shares of Clarient, 100% of the previously outstanding preferred shares of Clarient and approximately 57.77% of the outstanding common and preferred shares of Clarient on an as converted basis.
Healing with Artificial Intelligence highlights the future of patient care